Adoptive cell therapy (ACT) with tumor-specific T cells has been shown to mediate durable
cancer regression. Tumor-specific T cells are also the basis of other therapies, notably …

The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

The conformational landscapes of peptide/human leucocyte antigen (pHLA) protein
complexes encompassing tumor neoantigens provide a rationale for target selection …

Recognition of antigens by T cell receptors (TCRs) is a key component of adaptive immunity.
Understanding the structures of these TCR interactions provides major insights into immune …

Identifying highly specific T cell receptors (TCRs) or antibodies against epitopic peptides
presented by class I major histocompatibility complex (MHC I) proteins remains a bottleneck …

Cancer risk is influenced by inherited mutations, DNA replication errors, and environmental
factors. However, the influence of genetic variation in immunosurveillance on cancer risk is …

We present the first quantum-centric simulations of noncovalent interactions using a
supramolecular approach. We simulate the potential energy surfaces (PES) of the water and …

Mutations in KRAS are some of the most common across multiple cancer types and are thus
attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates …

Effectively targeting intracellular tumor-associated proteins presents a formidable challenge
in oncology, as they are traditionally considered inaccessible to conventional antibody …